Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07508358 | Vaginal Sildenafil for Primary Dysmenorrhea(SILDYS) | not yet recruiting | Phase 1 | 10 | Kevin HellmanOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | not yet recruiting | Phase 1 | 18 | ImmunityBio, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07800507 | Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07828249 | Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma(PRadR2) | not yet recruiting | Phase 1 | 26 | Centre Leon BerardOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | not yet recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07803653 | IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 1 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07796490 | Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07793578 | Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 32 | VA Office of Research and DevelopmentFED | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07783815 | A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure | not yet recruiting | Phase 1 | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07783282 | A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | not yet recruiting | Phase 1 | 56 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Aug 24, 2026 | clinicaltrials |
| NCT07778498 | A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 150 | Phrontline BiopharmaINDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07772882 | Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer | not yet recruiting | Phase 1 | 24 | Rebecca ArendOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07768306 | Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM | not yet recruiting | Phase 1 | 20 | Norroy Bioscience Co., LTDINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07765940 | Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer(COPRA424) | not yet recruiting | Phase 1 / Phase 2 | 52 | RadAlliance Therapeutics, IncINDUSTRY | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07756593 | Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer | not yet recruiting | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | not yet recruiting | Phase 1 / Phase 2 | 67 | CoRegen, Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07716735 | Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer | not yet recruiting | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07743541 | Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy(NAPISTAR 1-03) | not yet recruiting | Phase 1 / Phase 2 | 100 | Tubulis GmbHINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07725796 | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC | not yet recruiting | Phase 1 | 30 | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07715747 | A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 128 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer(RegeNovar) | not yet recruiting | Phase 1 / Phase 2 | 43 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07686744 | Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma(NPVPP) | not yet recruiting | Phase 1 | 8 | Jian LinOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07682649 | Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer(ESCENDO) | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683013 | Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 18 | Hyundai Bioscience Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07679841 | Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients(COLOMBE) | not yet recruiting | Phase 1 / Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | not yet recruiting | Phase 1 | 19 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07664397 | Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | not yet recruiting | Phase 1 | 40 | Robert Flavell, MD, PhDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07664735 | A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | not yet recruiting | Phase 1 | 30 | Outpace Bio, Inc.INDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07636707 | QLF4113 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 1 | 140 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07260162 | Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)(PERSEVERANCE) | not yet recruiting | Phase 1 | 24 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07495293 | Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer | not yet recruiting | Phase 1 | 20 | Yonsei UniversityOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07564102 | dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy | not yet recruiting | Phase 1 / Phase 2 | 30 | Mochida Medical USA, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07555769 | Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial(CALCIFER) | not yet recruiting | Phase 1 | 20 | Juan Luis VásquezOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | not yet recruiting | Phase 1 | 48 | Kumquat Biosciences Inc.INDUSTRY | 0 | Apr 21, 2026 | clinicaltrials |
| NCT07532148 | Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | not yet recruiting | Phase 1 | 24 | Chong Kun Dang PharmaceuticalINDUSTRY | 0 | Apr 15, 2026 | clinicaltrials |
| NCT07500805 | UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma | not yet recruiting | Phase 1 | 21 | UTC Therapeutics Inc.INDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07462468 | A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. | not yet recruiting | Phase 1 | 36 | WestVac Biopharma Co., Ltd.INDUSTRY | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07468396 | A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer | not yet recruiting | Phase 1 | 65 | Gan & Lee Pharmaceuticals.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials